ArticleJournal of cellular and molecular medicine2026
Corylin Confers Vasoprotection via JDP2-Nrf2 Antioxidant Axis against Chronic Kidney Disease-Induced Smooth Muscle Cell Remodelling.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vascular calcification is a pathological process involving vascular smooth muscle cells (VSMCs) phenotypic switching into osteoblast-like cells within a calcium phosphate-deposited environment. This transformation is a critical risk factor for cardiovascular morbidity and mortality in patients with hyperphosphatemia due to chronic kidney disease. Corylin, a major compound derived from the Chinese medicine herb Psoralea corylifolia, is beneficial for the cardiovascular system. However, its role in modulating VSMC phenotypic switching and calcification remains to be elucidated. A vascular calcification rat model induced by vitamin D3 plus nicotine (VDN) was established to evaluate the therapeutic effects of corylin. The protective effects of corylin were evaluated in high phosphate-induced vessels and VSMCs using cytotoxicity assay, Alizarin red S staining, alkaline phosphatase staining, immunofluorescence, Western blot analysis, and qPCR. The interaction between Jun dimerisation protein 2 (JDP2) and Nrf2 was analysed using a ChIP-qPCR assay. Corylin treatment ameliorated arteriosclerotic lesions and oxidative stress in rats treated with VDN. We also observed that the cytoprotective effects of corylin prevented VSMC apoptosis and deposition of calcium phosphates. Additionally, corylin decreased calcium overload by inhibiting calcineurin and maintaining mitochondrial homeostasis. We identified a robust co-induction of JDP2 and Nrf2 in corylin-treated VSMCs, which contributed to reducing phenotypic switching and abrogating oxidative stress. Furthermore, Nrf2 knockdown by an inhibitor abolished JDP2 activation and the protective effects of corylin. Our study reveals that corylin exerts anti-arteriosclerotic and vasculoprotective effects targeting JDP2-Nrf2 activation, making it a potential treatment for vascular calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.